Presence of central nervous system (CNS) involvement requiring active treatment Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization Current or past history of central nervous system (CNS) disease, or CNS involvement by MM Symptomatic central nervous system (CNS) involvement which are neurologically unstable or requiring increasing doses of steroids to control. Central nervous system (CNS) involvement Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < Subject has confirmed central nervous system (CNS) involvement by DLBCL. Subjects at risk for CNS involvement per Investigator assessment must receive prophylaxis. For subjects at risk, or with any neurological symptoms, testing for CNS involvement is required at Screening. Has clinical signs of central nervous system (CNS) involvement of MM. Central Nervous System (CNS) involvement with multiple myeloma defined as csf positivity for plasma cells or a parenchymal CNS plasmacytoma Active central nervous system (CNS) involvement by malignancy, except in cases of virus-associated malignancies with CNS involvement in which case the patient may benefit from the transplant to control the malignancy Known clinically active central nervous system (CNS) involvement; prior evidence of CNS involvement successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment and there are no neurological signs of potential CNS involvement Prior central nervous system (CNS) involvement by tumor cells; Active central nervous system (CNS) involvement by malignancy Patients with history of central nervous system (CNS) involvement Active central nervous system (CNS) metastases and/or leptomeningeal involvement The toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknown Evidence of active central nervous system (CNS) involvement Central nervous system (CNS) involvement, including lymphomatous meningitis Prior central nervous system (CNS) involvement by tumor cells No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet ALL of the following to be eligible: Active central nervous system (CNS) involvement or leptomeningeal involvement Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven) Active, untreated central nervous system (CNS) involvement Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study) Central nervous system (CNS) involvement Uncontrolled central nervous system (CNS) involvement by tumor cells within the past months Central nervous system (CNS) involvement History of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvement Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven) Active central nervous system (CNS) involvement within the previous months Active central nervous system (CNS) involvement of the underlying malignancy Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration Central nervous system (CNS) involvement Active central nervous system (CNS) neoplastic involvement Patients with central nervous system (CNS) metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions) Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment Central nervous system (CNS) involvement within months Patient must have no current or prior history of central nervous system (CNS) involvement Patient with active central nervous system (CNS) involvement Patients with active central nervous system (CNS) involvement by malignant cells Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study) Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease. Patient has distant metastatic disease, including central nervous system (CNS) tumor involvement Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria: Symptomatic central nervous system (CNS) involvement by AML Untreated central nervous system (CNS) involvement Active central nervous system (CNS) involvement or leptomeningeal metastases involvement Uncontrolled central nervous system (CNS) disease involvement Has known clinically active central nervous system (CNS) involvement OR history of resolved CNS involvement by multiple myeloma Patients with history of central nervous system (CNS) involvement or active CNS involvement by malignancy Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < Active central nervous system (CNS) involvement by malignancy Active Central Nervous System (CNS) involvement by malignancy Have active leukemic involvement of the central nervous system (CNS). Patients who have symptomatic central nervous system (CNS) involvement are not eligible Active central nervous system (CNS) involvement of disease Central nervous system (CNS) involvement. Patients with documented central nervous system (CNS) involvement Participants with active central nervous system (CNS) involvement are excluded; patients with suspected CNS disease should be worked up appropriately prior to enrollment Patient has active or history of central nervous system (CNS) disease or meningeal involvement Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration Central nervous system (CNS) involvement by CLL. Research participants with known brain metastases (central nervous system [CNS] involvement either parenchymal or leptomeningeal involvement) Has evidence of uncontrolled central nervous system (CNS) involvement (previous radiation and off steroids is acceptable) History of central nervous system (CNS) involvement by myeloma Patients with central nervous system (CNS) involvement Untreated central nervous system (CNS) involvement; (treated CNS involvement is permitted only if the patient is not currently on steroid therapy or has remained on a stable, unchanged dose of steroid for >= weeks) Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast magnetic resonance imaging (MRI) for at least months prior to study entry Patient with active central nervous system (CNS) involvement with lymphoid malignancy Uncontrolled central nervous system (CNS) involvement with disease Evidence of AML central nervous system (CNS) involvement Central nervous system (CNS) involvement. Active diagnosis of central nervous system (CNS) involvement with CLL Active central nervous system (CNS) involvement by malignancy (defined as CNS- per National Comprehensive Cancer Network [NCCN] guidelines) Patient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded. Central nervous system (CNS) involvement of DLBCL Active central nervous system (CNS) disease involvement Clinically active central nervous system (CNS) cancer involvement. Imaging to exclude CNS involvement not required. Symptomatic central nervous system (CNS) involvement Had evidence of active central nervous system (CNS) involvement Symptomatic central nervous system (CNS) involvement Active or symptomatic central nervous system (CNS) disease or epidural involvement Evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration Symptomatic, steroid-requiring or progressive central nervous system (CNS) involvement Active involvement of the Central Nervous System (CNS). Clinically uncontrolled central nervous system (CNS) involvement Patients with central nervous system (CNS) metastatic involvement. Clinically uncontrolled central nervous system (CNS) involvement Active central nervous system (CNS) involvement of their malignancy. Uncontrolled central nervous system (CNS) involvement by tumor cells Active central nervous system (CNS) involvement by malignancy Prior central nervous system (CNS) involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment. Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration History of central nervous system (CNS) involvement Patient must not have active central nervous system (CNS) involvement Active central nervous system (CNS) involvement by malignant cells EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment) Active central nervous system (CNS) involvement by malignant cells Active central nervous system (CNS) involvement by malignant cells Active central nervous system (CNS) involvement by malignant cells Clinical signs of central nervous system (CNS) involvement of MM.